Compare AbCellera Biologics Inc (ABCL) vs State Street SPDR Bloomberg 1-3 Month T-Bill ETF (BIL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs State Street SPDR Bloomberg 1-3 Month T-Bill ETF — how do they compare? AbCellera Biologics Inc trades at $7.45 (market cap $2.35B), while State Street SPDR Bloomberg 1-3 Month T-Bill ETF trades at $91.46. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, State Street SPDR Bloomberg 1-3 Month T-Bill ETF nearer its low. Which is the better fit depends on your goals.
| ABCL | BIL | |
|---|---|---|
Market Cap | $2.35B | — |
Sector | Health | Fixed Income |
52-Week High | $8.12 | $91.77 |
52-Week Low | $2.78 | $91.27 |
Enterprise Value | $1.99B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
BIL trades at $91.43, down slightly by 0.01% over 24 hours, with a bearish technical outlook indicated by moving averages. The ETF maintains a consistent dividend payout of $0.27 per share, with recent distributions in H1-26 and upcoming in H2-26. Market sentiment is influenced by Federal Reserve rate hike speculation, as bond ETF inflows surge amid inflation concerns and stock volatility.
The outlook for BIL is cautious due to potential interest rate hikes in 2026, which could impact short-term Treasury yields. Risks include Fed policy uncertainty and macroeconomic shifts, but the ETF offers stability through regular dividends. Investors should weigh yield opportunities against interest rate sensitivity in the current environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL tracks the performance of short-term U.S. Treasury bills with maturities between 1 and 3 months. It is designed for investors seeking a highly liquid, low-risk vehicle for cash management and capital preservation.
Read more on BIL →
